Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.59 |
| ▸ | PPARA | Q07869 | 18/20 | 0.59 |
| ▸ | PPARD | Q03181 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106094 | 0.98 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL6701051 | 0.97 | PPARG (0.58) | PPARGPPARAPPARDKDM4EALDH1A1 | |
| SCHEMBL5105446 | 0.95 | PPARG (0.60) | PPARGPPARAPPARDKDM4EALDH1A1 | |
| SCHEMBL5102561 | 0.93 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL5098317 | 0.93 | PPARG (0.63) | PPARGPPARAPPARD | |
| SCHEMBL6701012 | 0.92 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL5112881 | 0.90 | PPARG (0.58) | PPARGPPARAPPARDKDM4EALDH1A1 | |
| SCHEMBL5098582 | 0.90 | PPARG (0.62) | PPARGPPARAPPARDKDM4EALDH1A1 | |
| SCHEMBL5110792 | 0.90 | PPARG (0.74) | PPARGPPARAPPARD | |
| SCHEMBL6702171 | 0.89 | PPARG (0.70) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825222-B2 | 2-(4-(2-(2-BIPHENYL-YL-5-METHYL-THIAZOL-4-YL)-ALKOXY)-PHENOXY) -2-METHYL-PROPIONIC ACID DERIVATIVES; ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040019090-A1 | 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents | ELI LILLY & COMPANY | 2004-01-29 | — | — | US | disclosed |
| EP-1206457-B1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6610696-B2 | Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides) | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY & COMPANY LILY CORPORATE CENTER (US) | 2003-03-06 | — | — | US | disclosed |
| WO-2001016120-A9 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6417212-B1 | PHENYLOXAZOLE SUBSTITUTED ON BENZENEOXYPROPIONIC ACID OR ESTERS | ELI LILLY & COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-1206457-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001016120-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019090-A1 | 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents | SLC5A2, SLC5A1, GLP1R | PPARG 26/4885PPARA 19/4885PPARD 68/4885 |
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.